The first standalone at-home sample collection kit received FDA approval, new research shows children are not spared from COVID-19 risk, and 4 more snapshots of key pandemic coverage from May.
Early data suggest a candidate vaccine for COVID-19 developed by the drug maker Moderna generates an immune response like the response seen in patients who have been infected and recovered from COVID-19. In a phase 1 clinical trial led by the National Institute of Allergy and Infectious Disease, 8 patients who received the vaccine developed neutralizing antibodies to SARS-CoV-2 at levels similar to those who had recovered from infection. Read the full article here.
When asked "Have you reopened your practice to patients in person," 89% of more than 1000 practice leaders surveyed responded "yes.“ The survey was conducted by the Medical Group Management Association on May 8, 2020. Among multiprovider practices that have reopened, more than half (54%) said that all of their clinicians are again seeing patients in person. Read the full article here.
The FDA issued an emergency use authorization (EUA) to Everlywell, Inc. for their COVID-19 Test Home Collection Kit, the only authorized at-home sample collection kit for use with multiple authorized diagnostic tests. The collection kit allows sample collection and transport laboratories that have been issued EUAs to test the specimens. Read the full article here.
A new cross-sectional study published May 11, 2020 in JAMA Pediatrics found that children, teenagers, and young adults are at greater risk for severe complications from COVID-19 than previously thought, and those with underlying health conditions are at an even greater risk. The study found that of 48 patients aged ≤21 years with COVID-19 who were admitted to pediatric intensive care units, >20% of patients experienced failure of ≥2 organ systems due to COVID-19, and approximately 40% required a breathing tube and ventilator. Read the full article here.
Medication adherence among patients with asthma and COPD appears to have increased during the initial phase of the COVID-19 pandemic, according to a new study in the Journal of Allergy and Clinical Immunology: In Practice. Using data from electronic medication monitors, researchers analyzed adherence to use of controller medication for 7578 patients. Comparison of adherence from early January to late March 2020 and found a 14.5% increase in mean daily controller medication adherence. Read the full article here.
The US FDA informed pharmaceutical manufacture ViralClear Pharmaceuticals, Inc, that it had completed its review of the company's IND application. The company announced that it may now proceed with its proposed phase II study of the antiviral agent merimepodib oral solution in adults with COVID-19 who are hospitalized and either require supplemental oxygen or are on non-invasive ventilation or high flow oxygen devices. Read the full article here.